- Home
- LXEH vs IXHL Comparison
LXEH vs IXHL Comparison
Compare LXEH & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LXEH | IXHL |
|---|---|---|
| Founded | 2001 | 2001 |
| Country | China | Australia |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 97.6M |
| IPO Year | 2020 | 2024 |
Fundamental Metrics
Financial Performance| Metric | LXEH | IXHL |
|---|---|---|
| Price | $0.23 | $5.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 669.9K | ★ 4.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.18 | $0.11 |
| 52 Week High | $50.08 | $5.45 |
Technical Indicators
Market Signals| Indicator | LXEH | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 50.13 | 90.18 |
| Support Level | $0.18 | $0.31 |
| Resistance Level | $0.28 | N/A |
| Average True Range (ATR) | 0.03 | 0.37 |
| MACD | 0.00 | 0.40 |
| Stochastic Oscillator | 25.09 | 91.05 |
Price Performance
Historical ComparisonAbout LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.